ALPMF
Astellas Pharma Inc.
18
On watch
Astellas Pharma's XTANDI drives 25.8% revenue growth amid high margins and low conviction.
The thesis
Astellas Pharma operates in the pharmaceutical sector with a diverse portfolio including XTANDI. The company has seen 25.8% YoY revenue growth. Its gross margin is 74.71% and net margin is 16.04%. The conviction score is 18/100, indicating low analyst conviction.
Why now
The current macro context of tightening monetary policy may impact consumer discretionary spending, but pharmaceuticals remain a defensive sector. Astellas Pharma's high revenue growth and margins make it an interesting watch.
What to watch
Investors should watch the company's upcoming revenue reports and any updates on XTANDI's market performance over the next quarter. Changes in analyst conviction scores and revisions to earnings estimates will also be important indicators.
Key risks
The key risks include valuation risk given its P/E of 11.8x and DCF intrinsic value of $30, and execution risk related to maintaining its high revenue growth rate. Macro risks related to regulatory changes or competition in the pharmaceutical sector are also relevant.
Theme exposure
Healthcare, Biotech & Devices
DirectAstellas Pharma Inc. operates in drug manufacturers - general. That places it inside the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
Market intelligence only. Not financial advice. Not a recommendation.